Danh mục

Rationale and design of a phase II trial of dacomitinib in advanced non-small cell lung cancer patients with uncommon epidermal growth factor receptor mutations: A prospective and single arm study (DANCE study)

Số trang: 6      Loại file: pdf      Dung lượng: 1.04 MB      Lượt xem: 7      Lượt tải: 0    
10.10.2023

Xem trước 2 trang đầu tiên của tài liệu này:

Thông tin tài liệu:

Dacomitinib is a second-generation, irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI). ARCHER-1050 showed that this agent can improve progression-free survival and overall survival in advanced non-small cell lung cancer patients with sensitive EGFR mutation compared to gefitinib.
Nội dung trích xuất từ tài liệu:
Rationale and design of a phase II trial of dacomitinib in advanced non-small cell lung cancer patients with uncommon epidermal growth factor receptor mutations: A prospective and single arm study (DANCE study)

Tài liệu được xem nhiều:

Gợi ý tài liệu liên quan: